Icure Pharmaceutical Incorporation reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was KRW 838.07 million compared to KRW 602.89 million a year ago. Net loss was KRW 38,166.94 million compared to KRW 12,614.18 million a year ago.

Basic loss per share from continuing operations was KRW 2,115 compared to KRW 767 a year ago. Diluted loss per share from continuing operations was KRW 2,115 compared to KRW 767 a year ago. Basic loss per share was KRW 2,115 compared to KRW 767 a year ago.